AR017457A1 - Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias. - Google Patents
Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.Info
- Publication number
- AR017457A1 AR017457A1 ARP990100570A ARP990100570A AR017457A1 AR 017457 A1 AR017457 A1 AR 017457A1 AR P990100570 A ARP990100570 A AR P990100570A AR P990100570 A ARP990100570 A AR P990100570A AR 017457 A1 AR017457 A1 AR 017457A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- integer
- range
- independently represent
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Un compuesto derivado de 2-(purin-9-il)-tetrahidrofuran-3,4-diol de la formula (I), donde R1 y R2 representan independientemente un grupo seleccionado de:cicloalquilo C3-8; hidrogeno; aril2CHCH2-; cicloalquil C3-8-alquilo C1-6; alquilo C1-8;arilaqui lo C1-6; R4R5N-alquilo C1-6; alquil C1-6-CH(CH2OH)-; arilalquilC1-5-CH(CH2OH)-; arilalquil C1-5-C(CH2OH)2-; cicloalquilo C3-8 independientemente sustituido por uno o más grupos -(CH2)pR6; H2NC(=NH)NHCalquilo C1-6; un grupode la formula (II)o tal gru po en el cual un átomo de C de metileno adyacente a X, o tanto si tal existe, se sustituye por metilo; alquil C1-6-OH; haloalquiloC1-8; un grupo de la formula (III); arilo; y -(CH2)fSO2NHg(alquilo C1-4)2-g o -(CH2)fSO2NHg(arilalquilo C1-4)2-g; R3 rep resenta metilo, etilo, -CH=CH2,n-propilo, -CH2CH=CH2, -CH=CHCH3, isopropenilo, ciclopropilo, ciclopropenilo, CH(OH)CH3, -(CH2)qhalogeno, -(CH2)hY(CH2)H, -COO(CH2)H, -CON(CH2)mH((CH2)nH),-CO(CH2)oH, o -C((CH2)uH)=NO(CH2)vH; a y brepresentan independi entemente un numero entero de 0 a 4 con la condicion que a + b esté enla gama de 3 a 5; c, d ye representan independientemente un numero entero de 0 a 3 con la condicion que c + d + e esté en la gama de 2 a 3; f representa 2 o3 y g representa un num eroentero de 0 a 2; p representa 0 o 1; q representa 1 o 2; h representa 1 o 2 e i representa un numero entero de 0 a 1; tal que h + i está enla gama de 1 a 2; jrepresenta un numero entero de 0 a 1 tal que h + i + j está enla gama de 1 a 2; l repres enta 1 o 2; m y n representan independientemente un numero entero de 0a 2 tal que m + n esté en la gama de 0 a 2; o representa un numero entero de 0 a 2; u y v representan independientemente 0 o 1 tal que u + v está en lagama de0 a 1; R4 y R5 repres entan independientemente hidrogeno, alquilo C1-6, arilo, arilaquilo C1-6 o NR4R5 conjuntamente pueden representar piridinilo,pirrolidinilo, piperidinilo, morfolinilo, azetidinilo, azepinilo, piperazinilo o N-alquil C1-6-piperazinilo; R6 representa OH , NH2, NHCOCH3 o halogeno; R7representa hidrogeno, alquilo C1-6, alquil C1-6-arilo o -COalquilo C1-6; X representa NR7, O, S, SO o SO2; aril representa un anillo carbocíclico, bicíclico o
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9803169.3A GB9803169D0 (en) | 1998-02-14 | 1998-02-14 | Chemical compounds |
| GBGB9813533.8A GB9813533D0 (en) | 1998-06-23 | 1998-06-23 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR017457A1 true AR017457A1 (es) | 2001-09-05 |
Family
ID=26313119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990100570A AR017457A1 (es) | 1998-02-14 | 1999-02-11 | Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6610665B1 (es) |
| EP (1) | EP1056759B1 (es) |
| JP (1) | JP2002503669A (es) |
| KR (1) | KR20010082512A (es) |
| AP (1) | AP2000001881A0 (es) |
| AR (1) | AR017457A1 (es) |
| AT (1) | ATE223429T1 (es) |
| AU (1) | AU757156B2 (es) |
| BR (1) | BR9907886A (es) |
| CA (1) | CA2319009A1 (es) |
| CO (1) | CO4990969A1 (es) |
| DE (1) | DE69902758T2 (es) |
| DK (1) | DK1056759T3 (es) |
| EA (1) | EA200000759A1 (es) |
| EE (1) | EE200000358A (es) |
| ES (1) | ES2183516T3 (es) |
| HK (1) | HK1032062A1 (es) |
| HR (1) | HRP20000538A2 (es) |
| HU (1) | HUP0100702A3 (es) |
| IL (1) | IL137402A0 (es) |
| IS (1) | IS5576A (es) |
| MA (1) | MA27121A1 (es) |
| NO (1) | NO20004045D0 (es) |
| NZ (1) | NZ505812A (es) |
| PE (1) | PE20000270A1 (es) |
| PL (1) | PL342396A1 (es) |
| PT (1) | PT1056759E (es) |
| SK (1) | SK12002000A3 (es) |
| SV (1) | SV1999000016A (es) |
| TR (1) | TR200002355T2 (es) |
| WO (1) | WO1999041267A1 (es) |
| YU (1) | YU50800A (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514949B1 (en) | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
| YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
| CO4990969A1 (es) * | 1998-02-14 | 2000-12-26 | Glaxo Group Ltd | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol |
| DE69910213T2 (de) | 1998-06-23 | 2004-07-01 | Glaxo Group Ltd., Greenford | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivate |
| GB9813565D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| GB9813554D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US7427606B2 (en) | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
| US7378400B2 (en) | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
| GB9930075D0 (en) * | 1999-12-20 | 2000-02-09 | Glaxo Group Ltd | Medicaments |
| US7638496B2 (en) | 2000-02-15 | 2009-12-29 | Valeant Pharmaceuticals North America | Nucleoside analogs with carboxamidine modified monocyclic base |
| GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
| GB0115178D0 (en) * | 2001-06-20 | 2001-08-15 | Glaxo Group Ltd | Compounds |
| WO2003029264A2 (en) | 2001-10-01 | 2003-04-10 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| US6930093B2 (en) * | 2003-07-10 | 2005-08-16 | Valeant Research & Development | Use of ribofuranose derivatives against inflammatory bowel diseases |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| TWI346109B (en) * | 2004-04-30 | 2011-08-01 | Otsuka Pharma Co Ltd | 4-amino-5-cyanopyrimidine derivatives |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| EP1778712B1 (en) | 2004-08-02 | 2013-01-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| WO2006028618A1 (en) | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| WO2006023272A1 (en) | 2004-08-02 | 2006-03-02 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having a2a agonist activity |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| US7910708B2 (en) | 2005-10-21 | 2011-03-22 | Novartis Ag | Anti-IL13 human antibodies |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| DE602007013441D1 (de) | 2006-09-29 | 2011-05-05 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
| CA2667962A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
| PL2231642T3 (pl) | 2008-01-11 | 2014-04-30 | Novartis Ag | Pirymidyny jako inhibitory kinazy |
| PT2391366E (pt) | 2009-01-29 | 2013-02-05 | Novartis Ag | Benzimidazoles substituídos para o tratamento de astrocitomas |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EP2464649A1 (en) | 2009-08-12 | 2012-06-20 | Novartis AG | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| NZ598220A (en) | 2009-08-17 | 2014-02-28 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| CA2771432A1 (en) | 2009-08-20 | 2011-02-24 | Novartis Ag | Heterocyclic oxime compounds |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| JP2014505088A (ja) | 2011-02-10 | 2014-02-27 | ノバルティス アーゲー | Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物 |
| JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン， エルエルシー | 複素環化合物およびその使用 |
| US9102671B2 (en) | 2011-02-25 | 2015-08-11 | Novartis Ag | Compounds and compositions as TRK inhibitors |
| UY34329A (es) | 2011-09-15 | 2013-04-30 | Novartis Ag | Compuestos de triazolopiridina |
| US9174994B2 (en) | 2011-11-23 | 2015-11-03 | Intellikine, Llc | Enhanced treatment regimens using mTor inhibitors |
| CN104245701A (zh) | 2012-04-03 | 2014-12-24 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
| EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| KR20170036037A (ko) | 2014-07-31 | 2017-03-31 | 노파르티스 아게 | 조합 요법 |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9414193D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
| TW528755B (en) * | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| CO4990969A1 (es) * | 1998-02-14 | 2000-12-26 | Glaxo Group Ltd | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol |
| DE69910213T2 (de) * | 1998-06-23 | 2004-07-01 | Glaxo Group Ltd., Greenford | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivate |
-
1999
- 1999-02-11 CO CO99008188A patent/CO4990969A1/es unknown
- 1999-02-11 AR ARP990100570A patent/AR017457A1/es active IP Right Grant
- 1999-02-11 PE PE1999000123A patent/PE20000270A1/es not_active Application Discontinuation
- 1999-02-12 AT AT99906229T patent/ATE223429T1/de not_active IP Right Cessation
- 1999-02-12 AP APAP/P/2000/001881A patent/AP2000001881A0/en unknown
- 1999-02-12 SK SK1200-2000A patent/SK12002000A3/sk unknown
- 1999-02-12 BR BR9907886-4A patent/BR9907886A/pt not_active IP Right Cessation
- 1999-02-12 MA MA25462A patent/MA27121A1/fr unknown
- 1999-02-12 PT PT99906229T patent/PT1056759E/pt unknown
- 1999-02-12 WO PCT/EP1999/000915 patent/WO1999041267A1/en not_active Application Discontinuation
- 1999-02-12 ES ES99906229T patent/ES2183516T3/es not_active Expired - Lifetime
- 1999-02-12 US US09/622,313 patent/US6610665B1/en not_active Expired - Fee Related
- 1999-02-12 DK DK99906229T patent/DK1056759T3/da active
- 1999-02-12 PL PL99342396A patent/PL342396A1/xx unknown
- 1999-02-12 CA CA002319009A patent/CA2319009A1/en not_active Abandoned
- 1999-02-12 KR KR1020007008866A patent/KR20010082512A/ko not_active Application Discontinuation
- 1999-02-12 EE EEP200000358A patent/EE200000358A/xx unknown
- 1999-02-12 AU AU26235/99A patent/AU757156B2/en not_active Ceased
- 1999-02-12 YU YU50800A patent/YU50800A/sh unknown
- 1999-02-12 TR TR2000/02355T patent/TR200002355T2/xx unknown
- 1999-02-12 EA EA200000759A patent/EA200000759A1/ru unknown
- 1999-02-12 EP EP99906229A patent/EP1056759B1/en not_active Expired - Lifetime
- 1999-02-12 NZ NZ505812A patent/NZ505812A/en unknown
- 1999-02-12 DE DE69902758T patent/DE69902758T2/de not_active Expired - Fee Related
- 1999-02-12 SV SV1999000016A patent/SV1999000016A/es not_active Application Discontinuation
- 1999-02-12 JP JP2000531459A patent/JP2002503669A/ja active Pending
- 1999-02-12 HU HU0100702A patent/HUP0100702A3/hu unknown
- 1999-02-12 IL IL13740299A patent/IL137402A0/xx unknown
-
2000
- 2000-07-25 IS IS5576A patent/IS5576A/is unknown
- 2000-08-11 NO NO20004045A patent/NO20004045D0/no unknown
- 2000-08-11 HR HR20000538A patent/HRP20000538A2/hr not_active Application Discontinuation
-
2001
- 2001-04-10 HK HK01102563A patent/HK1032062A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR017457A1 (es) | Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias. | |
| AR014974A1 (es) | Compuestos con actividad sobre receptores muscarinicos, una composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de unmedicamento | |
| ES2037930T3 (es) | Preparaciones acuosas adecuadas como masas de obturacion o adhesivos para baldosas ceramicas. | |
| AR032130A1 (es) | Un compuesto inhibidor de quinasas proteicas, una composicion farmaceutica que lo incluye, y un metodo para tratar afecciones con dicho compuesto | |
| AR037929A1 (es) | Un compuesto derivado funcional del acido hidroxamico o caloxilico, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento para el tratamiento de trastornos inflamatorios | |
| AR014785A1 (es) | Derivados de pirimidina, uso de dichos derivados para la preparacion de medicamentos para el tratamiento de hiv,composicion farmaceutica que los comprende,procedimiento para prepararla, procedimiento para preparar dichos derivados, e intermediarios utiles en la preparacion de dichos derivados. | |
| AU1570583A (en) | N-heterocyclylsulphonyl-n:-pyrimidinyl (and thiazinyl)-ureas | |
| DK422583D0 (da) | Fremgangsmade til fremstilling af diazobicyclo-(3,3,1)-nonaner | |
| ES2049256T3 (es) | Composicion absorbente de gases acidos. | |
| EP0098098A3 (en) | Acridinecarboxamide compounds | |
| MX174156B (es) | Derivados de -aril-4-(4,5-dihidro-3,5-dioxo-1,2,4-triazin-2(3h)-il)-bencenacetonitrilo antiprotozoarios y composiciones farmaceuticas que los contienen | |
| JO1645B1 (en) | Pyridazine compounds are antibacterial viruses | |
| ES2045044T3 (es) | Derivados de sulfonamidolfenilo y agentes terapeuticos y preventivos de la arritmia que contienen los mismos. | |
| YU47219B (sh) | Antivirusna tetrahidroimidazo (1,4) benzodiazepin-2-tiona jedinjenja i postupak za njihovo dobijanje | |
| AR017072A1 (es) | Compuestos derivados de pirrolopirrolona como inhibidores de elastasa neutrofilica, uso de dichos compuestos, metodos de tratamiento, procesos depreparacion e intermediarios utiles para su produccion | |
| ATE186302T1 (de) | Etoposidanaloge | |
| BG35322A3 (en) | Herbicide means | |
| NO871194D0 (no) | N,n[-substituerte bis-(2,4-diamino-s-triazin-6-yl)-tetrasulfider og deres disproporsjoneringsprodukter, fremgangsmaate til deres fremstilling og deres anvendelse i vulkaniserbare kautsjukblandinger. | |
| GB672971A (en) | Improvements in esters and pest-combating agents containing them and in their manufacture | |
| JPS5227753A (en) | Prostaglandin analogues, their preparation, and pharmaceutical composi tions containing the same as active ingredient | |
| ZA851127B (en) | New 3-phenyl-2-propeneamine derivatives,their preparation and compositions containing them | |
| ES2123739T3 (es) | Nuevos analogos del eburnano, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
| ES2167563T3 (es) | Derivados de (2-morfolinilmetil)benzamida. | |
| JPS5590555A (en) | Organopolysiloxane composition for cleaning of teeth | |
| ES441183A1 (es) | Un procedimiento para preparar derivados de fosforotiolato. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |